Company intelligence / Profile preview

Aerovate Therapeutics

Waltham, Massachusetts, United Statesaerovatetx.com ↗

Ownership: Public · AVTE
Employees: ~30
Development stage: Phase 2

Overview

The Phase 2b IMPAHCT trial for AV-101 failed to meet its primary endpoint for improvement in PAH compared to placebo for any of the studied doses. The drug also failed to show meaningful improvements in the secondary endpoint of change in six-minute walk distance. As a result, the Phase 3 and long-term extension arms were stopped, and the company announced a 78% workforce reduction in July 2024[10].

Therapeutic areas: Rare DiseasesCardiovascular
Modalities: Small molecules (specifically inhaled dry powder formulation)
Industry: Biotech

Drug pipeline

1 asset

imatinib

Phase 2

Indications: Pulmonary Arterial Hypertension (PAH)

Financials

Market cap: $77.7M
Total revenue: $0
Enterprise value: $-28.9M

Beyond the preview

Go deeper on Aerovate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aerovate Therapeutics.

Explore the full profile